ArticleAdvanced science (Weinheim, Baden-Wurttemberg, Germany)2026
Restoration of m6A-Modified circPSMB1 Suppresses Chordoma Progression and Enables Local Nanotherapeutic Intervention.
Article in Advanced science (Weinheim, Baden-Wurttemberg, Germany), 2026. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
Abstract
Chordoma is a rare malignant bone tumor characterized by aggressive local invasion and high recurrence, yet its molecular regulatory mechanisms remain poorly understood. Circular RNAs (circRNAs) have emerged as important regulators of gene expression, but how circRNA epigenetic modifications contribute to oncogenic signaling is largely unknown. Here, we identify circPSMB1 as a significantly downregulated circRNA in chordoma tissues through high-throughput circRNA sequencing. Functionally, circPSMB1 suppresses chordoma cell proliferation, migration, and invasion in vitro and inhibits tumor growth in vivo. Mechanistically, METTL3-dependent m6A modification facilitates the association of circPSMB1 with the m6A reader HNRNPA2B1. CircPSMB1 competitively reduces the association of HNRNPA2B1 with c-MYC mRNA, thereby decreasing c-MYC protein expression without altering c-MYC transcript abundance. Beyond mechanistic insight, we develop an injectable circPSMB1-loaded HMnO
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.